[HTML][HTML] Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
YY Janjigian, BJ Park, MF Zakowski, M Ladanyi… - Journal of Thoracic …, 2011 - Elsevier
Background: Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
YY Janjigian, BJ Park, MF Zakowski… - Journal of thoracic …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
[HTML][HTML] Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor …
YY Janjigian, BJ Park, MF Zakowski… - Journal of thoracic …, 2011 - ncbi.nlm.nih.gov
Background Patients with stage IV lung adenocarcinoma and EGFR mutation derive clinical
benefit from treatment with EGFR tyrosine kinase inhibitors (TKI). Whether treatment with TKI …
benefit from treatment with EGFR tyrosine kinase inhibitors (TKI). Whether treatment with TKI …
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
YY Janjigian, BJ Park, MF Zakowski… - Journal of Thoracic …, 2011 - europepmc.org
Background Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
[PDF][PDF] Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
YY Janjigian, BJ Park, MF Zakowski… - Journal of Thoracic …, 2011 - core.ac.uk
Background: Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
YY Janjigian, BJ Park, MF Zakowski, M Ladanyi… - Journal of Thoracic …, 2011 - jto.org
Background: Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
[引用][C] Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
YY Janjigian, BJ Park, MF Zakowski… - Journal of Thoracic …, 2011 - cir.nii.ac.jp
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected
Lung Adenocarcinomas that Harbor EGFR Mutations | CiNii Research CiNii 国立情報学研究所 …
Lung Adenocarcinomas that Harbor EGFR Mutations | CiNii Research CiNii 国立情報学研究所 …
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
YY Janjigian, BJ Park, MF Zakowski… - Journal of Thoracic …, 2011 - europepmc.org
Background Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …